The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 13, 2009
Filed:
Jun. 11, 2002
Frans Eduard Janssens, Bonheiden, BE;
Joseph Elisabeth Leenaerts, Rijkevorsel, BE;
Koenraad Arthur Van Rossem, Vosselaar, BE;
Manuel Jesús Alcázar-vaca, Toledo, ES;
Pedro Martínez-jiménez, Madrid, ES;
José Manuel Bartolomé-nebreda, Toledo, ES;
Antonio Gómez-sánchez, Toledo, ES;
Francisco Javier Fernández-gadea, Toledo, ES;
Jos Van Reempts, Geel, BE;
Frans Eduard Janssens, Bonheiden, BE;
Joseph Elisabeth Leenaerts, Rijkevorsel, BE;
Koenraad Arthur Van Rossem, Vosselaar, BE;
Manuel Jesús Alcázar-Vaca, Toledo, ES;
Pedro Martínez-Jiménez, Madrid, ES;
José Manuel Bartolomé-Nebreda, Toledo, ES;
Antonio Gómez-Sánchez, Toledo, ES;
Francisco Javier Fernández-Gadea, Toledo, ES;
Jos Van Reempts, Geel, BE;
Janssen Pharmaceutica N.V., Beerce, BE;
Abstract
The invention concerns novel substituted tetracyclic imidazole derivatives useful for the treatment of elevated intracranial pressure (ICP) and/or secondary ischaemia, in particular caused by brain injury, more in particular caused by traumatic (TBI) and non-traumatic brain injury, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine. The novel compounds comprise compounds according to the general Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof. In particular, the preferred compound is 3-[2-[4-(11,12-dihydro-6H-benzimidazo[2,1-b][3]benzazepin-6-yl)-2-(phenyl-l-methyl)-1-piperidinyl]ethyl]-2,10-dimethyl pyrimido[1,2-α]benzimidazol-4(10H)-one, the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof.